What will pharma's share buyback shopping spree mean for M&A?
A handful of cash-rich pharma companies have announced billions of dollars in share buybacks in recent months, raising questions about their interest in transformative dealmaking …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
